50% off all subscriptions! ... left. Order NowOrder Now

CTI BioPharma Corp. Stock Forecast NASDAQ:CTIC

$2.48 (5.98%)

Volume: 2M

Closed: Nov 26, 2021

Hollow Logo Score: -2.086

CTI BioPharma Corp. Stock Forecast

$2.48 (5.98%)

Volume: 2M

Closed: Nov 26, 2021

Score Hollow Logo -2.086
Which way will CTIC go? Request
Key Stats
P/E Ratio -5.25
Beta 0.34
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 38 and the stock is currently not being overbought or oversold

CTI BioPharma Corp. stock price up more than 5.98% on Friday
(Updated on Nov 26, 2021)

Sell candidate since 2021-11-17 Loss -1.98%

The CTI BioPharma Corp. stock price gained 5.98% on the last trading day (Friday, 26th Nov 2021), rising from $2.34 to $2.48. During the day the stock fluctuated 6.64% from a day low at $2.41 to a day high of $2.57. The price has fallen in 6 of the last 10 days and is down by -1.98% for this period. Volume fell on the last day by -430 thousand shares and in total, 2 million shares were bought and sold for approximately $3.87 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -19.77% during the next 3 months and, with a 90% probability hold a price between $1.84 and $2.15 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Signals & Forecast

There are mixed signals in the stock today. The CTI BioPharma Corp. stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term moving average at $2.63. On a fall, the stock will find some support from the short-term average at $2.43. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). A buy signal was issued from a pivot bottom point on Wednesday, November 24, 2021, and so far it has risen 5.98%. Further rise is indicated until a new top pivot has been found. Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely.

Support, Risk & Stop-loss

CTI BioPharma Corp. finds support from accumulated volume at $2.41 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.16 between high and low, or 6.64%. For the last week, the stock has had a daily average volatility of 5.62%.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is CTI BioPharma Corp. stock A Buy?

CTI BioPharma Corp. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -2.086

Predicted Opening Price for CTI BioPharma Corp. of Monday, November 29, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price November 29, 2021 Current price
$2.49 $2.48 (Undervalued)
Sell Candidate Unchanged

Remember To Visit Our YouTube Channel

Analyst Ratings

On Nov 17, 2021 "JMP Securities" gave "$4.00" rating for CTIC. The price target was changed from $2.63 to 3.0%.

Volatility and Risk
Daily Average Volatility: 5.62 %
Overall Risk: Very High High Medium Low Very Low
5.62 %
Daily Average Volatility
Overall Risk

Very High
Very Low

Support & Resistance

Resistance: $2.53
Price: $2.48
Support: $2.41

CTIC Insider Trading Show all Trades



Last 100 transactions
Buy: 28 923 375 | Sell: 7 096 677 (Shares)
Date Action Amount Person Type
Apr 01, 2021 Buy 1 044 813 Bvf Partners L P/il Common Stock, par value $0.001
Apr 01, 2021 Buy 950 016 Bvf Partners L P/il Common Stock, par value $0.001
Apr 01, 2021 Buy 5 171 Bvf Partners L P/il Common Stock, par value $0.001
Apr 01, 2021 Buy 344 Bvf Partners L P/il Series X1 Convertible Preferred Stock
Apr 01, 2021 Buy 239 Bvf Partners L P/il Series X1 Convertible Preferred Stock
Show all Insider Trades


Last 100 transactions
Buy: 28 923 375 | Sell: 7 096 677 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 2.65 6.72 %
2.59 4.26 %
2.55 2.73 %
Current price: 2.48
Support 2.43 -2.20 %
2.39 -3.72 %
2.33 -6.18 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 2.71 9.27 %
2.67 7.66 %
2.53 2.02 %
Current price 2.48
Support 2.41 -2.82%
2.35 -5.24%
2.34 -5.65%

Click to get the best stock tips daily for free!

About CTI BioPharma Corp.

CTI BioPharma CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also devel... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE